Skip to Main Content

Paper Details

Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy.
Clin Cancer Res
11
2022
CD4+, CTLA-4, CaboNivo, Cabozantinib, M-MDSC, Metastatic Urothelial Carcinoma, Nivolumab, Patients, TIM-3, Tregs, antitumor immune subsets, cabozantinib, effector CD4+ T cells, effector T cells, mUC, metastatic urothelial carcinoma, monocytic, monocytic myeloid-derived suppressor cells, nivolumab, nonclassical monocytes, patients, peripheral blood immune subsets, polymorphonuclear MDSCs, regulatory, regulatory T cells
Author NameAffiliation
Primo N LaraUniversity of California Davis Comprehensive Cancer Center
Seth M SteinbergOffice of the Clinical Director, Center for Cancer Research
Seth M SteinbergOffice of the Clinical Director, Center for Cancer Research
Keith Syson ChanSamuel Oschin Cancer Center, Cedars Sinai Medical Center
Yunkai YuCenter for Cancer Research
Yunkai YuCenter for Cancer Research
Maria J MerinoCenter for Cancer Research
Maria J MerinoCenter for Cancer Research
Liang CaoCenter for Cancer Research
Liang CaoCenter for Cancer Research
  • 1 - 10

Datasets

Release 1.2